TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1/14/21 17:54 | 1/12/21 | CGEM | Cullinan Management, Inc. | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | E9 | T | P.d | 6,300 | 21.00 | 0 | 300 | 4 | 7,914 | D | ||||||||||||||||
10/8/20 18:26 | 10/6/20 | ONCR | Oncorus, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Ubs Oncology Impact Fund L.P. | E9 | T | P.d | 2,268 | 15.00 | 0 | 151 | 7 | 2,377 | D | |||||||||||||||
2/21/19 18:06 | 2/19/19 | TCRR | Tcr2 Therapeutics Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | P.d | 10,000 | 15.00 | 0 | 667 | 25 | 3,371 | D | |||||||||||||||
2/14/19 17:34 | 2/12/19 | HARP | Harpoon Therapeutics, Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Ubs Oncology Impact Fund L.P. | MA | T | P.d | 3,500 | 14.00 | 0 | 250 | 7 | 3,898 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |